Cellectar Biosciences, Inc. — Regulatory Filings 2021

Jan 29, 2021

CORRESP 1 filename1.htm

CELLECTAR BIOSCIENCES, INC.

100 Campus Drive

Florham Park, New Jersey 07932

January 28, 2021

VIA EDGAR

Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Attention: Ms. Kasey Robinson

Re:
Registration Statement on Form S-3
File No. 333-252309 Acceleration Request Requested Date: Monday, February
1, 2021 Requested Time: 5:00 P.M. Eastern
Time

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended, Cellectar Biosciences, Inc., a Delaware corporation (the “Company”), hereby requests that the effective date of the Company’s Registration Statement on Form S-3 (Registration No. 333-252309) be accelerated so that the Registration Statement will become effective at 5:00 p.m. on February 1, 2021, or as soon as practicable thereafter , or at such later time as the Company or its legal counsel may orally request via telephone call to the staff. The Company hereby authorizes Gregory J. Lynch or Joshua B. Erekson of Michael Best & Friedrich LLP to make such request on its behalf.

The cooperation of the staff in meeting our request is very much appreciated. If you have any questions or comments, please contact Gregory J. Lynch of Michael Best & Friedrich LLP at (608) 283-2240 or gjlynch@michaelbest.com or Joshua B. Erekson of Michael Best & Friedrich LLP at (801) 833-0505 or jberekson@michaelbest.com. Thank you for your assistance with these matters.

Very truly yours,
CELLECTAR BIOSCIENCES, INC.
By:	/s/ Dov Elefant
	Dov Elefant, Vice President and Chief Financial Officer

cc: James V. Caruso Gregory J. Lynch Joshua B. Erekson

Field: Page; Sequence: 1; Options: NewSection Last

Field: /Page